Anouchka P Laurent
Overview
Explore the profile of Anouchka P Laurent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu X, Mo S, Buendia A, Laurent A, Shao A, Alvarez-Torres M, et al.
Nature
. 2025 Jan;
637(8047):965-973.
PMID: 39779852
Transcriptional regulation, which involves a complex interplay between regulatory sequences and proteins, directs all biological processes. Computational models of transcription lack generalizability to accurately extrapolate to unseen cell types and...
2.
Carey-Smith S, Simad M, Panchal K, Aya-Bonilla C, Smolders H, Lin S, et al.
Haematologica
. 2024 Mar;
109(7):2309-2315.
PMID: 38426275
No abstract available.
3.
Shih B, Ma C, Cortes J, Reglero C, Miller H, Quinn S, et al.
J Invest Dermatol
. 2024 Jan;
144(7):1579-1589.e8.
PMID: 38219917
Cutaneous T-cell lymphomas are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T-cells. A distinctive clinical feature of cutaneous T-cell lymphomas is their sensitivity to treatment with histone...
4.
Reglero C, Dieck C, Zask A, Forouhar F, Laurent A, Lin W, et al.
Cancer Discov
. 2022 Aug;
12(11):2646-2665.
PMID: 35984649
Significance: Relapse-associated NT5C2 mutations directly contribute to relapse in ALL by driving resistance to chemotherapy with 6-MP. Pharmacologic inhibition of NT5C2 with CRCD2, a first-in-class nucleotidase inhibitor, enhances the cytotoxic...
5.
Cortes J, Filip I, Albero R, Patino-Galindo J, Quinn S, Lin W, et al.
Cell Rep
. 2022 Apr;
39(3):110695.
PMID: 35443168
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) comprises heterogeneous lymphoid malignancies characterized by pleomorphic lymphocytes and variable inflammatory cell-rich tumor microenvironment. Genetic drivers in PTCL-NOS include genomic alterations affecting...
6.
Cortes J, Patrone C, Quinn S, Gu Y, Sanchez-Martin M, Mackey A, et al.
J Invest Dermatol
. 2021 Jun;
141(12):2908-2920.e7.
PMID: 34089720
Sézary syndrome is an aggressive and disseminated form of cutaneous T-cell lymphoma associated with dismal prognosis in which the histone deacetylase inhibitor romidepsin has shown remarkable activity as a single...
7.
Bhansali R, Rammohan M, Lee P, Laurent A, Wen Q, Suraneni P, et al.
J Clin Invest
. 2021 Jan;
131(1).
PMID: 33393494
DYRK1A is a serine/threonine kinase encoded on human chromosome 21 (HSA21) that has been implicated in several pathologies of Down syndrome (DS), including cognitive deficits and Alzheimer's disease. Although children...
8.
Laurent A, Kotecha R, Malinge S
Leukemia
. 2020 May;
34(8):1984-1999.
PMID: 32433508
Structural and numerical alterations of chromosome 21 are extremely common in hematological malignancies. While the functional impact of chimeric transcripts from fused chromosome 21 genes such as TEL-AML1, AML1-ETO, or...
9.
Laurent A, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, et al.
Clin Cancer Res
. 2020 Mar;
26(13):3307-3318.
PMID: 32220889
Purpose: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse,...
10.
Rivera-Munoz P, Laurent A, Siret A, Lopez C, Ignacimouttou C, Cornejo M, et al.
Blood Adv
. 2018 Jul;
2(13):1616-1627.
PMID: 29986854
JAK3-activating mutations are commonly seen in chronic or acute hematologic malignancies affecting the myeloid, megakaryocytic, lymphoid, and natural killer (NK) cell compartment. Overexpression models of mutant JAK3 or pharmacologic inhibition...